Elaine Willmore

2.2k total citations
54 papers, 1.7k citations indexed

About

Elaine Willmore is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Elaine Willmore has authored 54 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 31 papers in Oncology and 20 papers in Genetics. Recurrent topics in Elaine Willmore's work include Cancer therapeutics and mechanisms (24 papers), Chronic Lymphocytic Leukemia Research (20 papers) and DNA Repair Mechanisms (12 papers). Elaine Willmore is often cited by papers focused on Cancer therapeutics and mechanisms (24 papers), Chronic Lymphocytic Leukemia Research (20 papers) and DNA Repair Mechanisms (12 papers). Elaine Willmore collaborates with scholars based in United Kingdom, United States and Italy. Elaine Willmore's co-authors include Caroline A. Austin, Michael J. Tilby, Barbara W. Durkacz, Miguel López‐Lázaro, Nicola J. Curtin, Graham Jackson, L. Mark Fisher, Nicola J. Sunter, Kay Padget and Adrian Frank and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Biochemistry.

In The Last Decade

Elaine Willmore

54 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elaine Willmore United Kingdom 23 1.4k 778 208 192 153 54 1.7k
Brent D. G. Page Canada 21 723 0.5× 758 1.0× 183 0.9× 92 0.5× 131 0.9× 52 1.6k
Wilberto Nieves‐Neira United States 17 1.2k 0.9× 671 0.9× 83 0.4× 72 0.4× 254 1.7× 29 1.7k
Dale Grabowski United States 22 1.1k 0.8× 650 0.8× 157 0.8× 97 0.5× 106 0.7× 67 1.4k
Victoria J. Spanswick United Kingdom 21 914 0.7× 462 0.6× 267 1.3× 114 0.6× 258 1.7× 39 1.3k
Yi‐He Ling United States 19 1.4k 1.0× 912 1.2× 257 1.2× 66 0.3× 234 1.5× 37 2.2k
Karen S. Flatten United States 24 1.4k 1.1× 814 1.0× 97 0.5× 44 0.2× 226 1.5× 45 1.9k
Jean‐Marc Barret France 20 905 0.7× 375 0.5× 225 1.1× 104 0.5× 117 0.8× 43 1.3k
Yoji Ikegami Japan 19 1.2k 0.8× 1.2k 1.6× 146 0.7× 203 1.1× 82 0.5× 43 1.9k
Fumihiko Kanzawa United Kingdom 21 1.0k 0.7× 914 1.2× 273 1.3× 167 0.9× 105 0.7× 80 1.6k
Erkan Baloglu United States 30 1.9k 1.4× 1.2k 1.5× 319 1.5× 32 0.2× 234 1.5× 85 3.0k

Countries citing papers authored by Elaine Willmore

Since Specialization
Citations

This map shows the geographic impact of Elaine Willmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elaine Willmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elaine Willmore more than expected).

Fields of papers citing papers by Elaine Willmore

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elaine Willmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elaine Willmore. The network helps show where Elaine Willmore may publish in the future.

Co-authorship network of co-authors of Elaine Willmore

This figure shows the co-authorship network connecting the top 25 collaborators of Elaine Willmore. A scholar is included among the top collaborators of Elaine Willmore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elaine Willmore. Elaine Willmore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wallis, Jonathan P., Helen Marr, Scott Marshall, et al.. (2025). Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia. Cancers. 17(2). 274–274. 2 indexed citations
2.
Nakjang, Sirintra, Jonathan P. Wallis, Helen Marr, et al.. (2024). RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia. Biomedicines. 12(7). 1388–1388. 4 indexed citations
3.
Willmore, Elaine, et al.. (2024). ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. British Journal of Cancer. 131(5). 905–917. 10 indexed citations
4.
Ciardullo, Carmela, Jonathan P. Wallis, Helen Marr, et al.. (2023). Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. International Journal of Molecular Sciences. 24(3). 2410–2410. 11 indexed citations
5.
Mulligan, Evan A., Susan J. Tudhope, Jill V. Hunter, et al.. (2023). Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling. Cancers. 15(19). 4736–4736. 4 indexed citations
6.
Wallis, Jonathan P., Helen Marr, Scott Marshall, et al.. (2023). SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 24(14). 11335–11335. 7 indexed citations
7.
Thijssen, Rachel, Christopher M. West, Louise Young, et al.. (2021). Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL. Cell Death and Differentiation. 28(5). 1658–1668. 66 indexed citations
8.
Barrow, Timothy M., Nicole Wong Doo, Roger L. Milne, et al.. (2020). Analysis of retrotransposon subfamily DNA methylation reveals novel early epigenetic changes in chronic lymphocytic leukemia. Haematologica. 106(1). 98–110. 14 indexed citations
9.
Iannetti, Alessio, Adeline Ledoux, Susan J. Tudhope, et al.. (2014). Regulation of p53 and Rb Links the Alternative NF-κB Pathway to EZH2 Expression and Cell Senescence. PLoS Genetics. 10(9). e1004642–e1004642. 85 indexed citations
10.
Sunter, Nicola J., et al.. (2010). Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide. Journal of Nucleic Acids. 2010(1). 16 indexed citations
11.
Elliott, Sarah L., Evan A. Mulligan, Geoffrey Summerfield, et al.. (2010). Mitoxantrone in combination with an inhibitor of DNA‐dependent protein kinase: a potential therapy for high risk B‐cell chronic lymphocytic leukaemia. British Journal of Haematology. 152(1). 61–71. 28 indexed citations
12.
López‐Lázaro, Miguel, Elaine Willmore, & Caroline A. Austin. (2009). The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 696(1). 41–47. 79 indexed citations
13.
Willmore, Elaine, Sarah L. Elliott, Tryfonia Mainou‐Fowler, et al.. (2008). DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia. Clinical Cancer Research. 14(12). 3984–3992. 73 indexed citations
14.
Jobson, Andrew G., Elaine Willmore, Michael J. Tilby, et al.. (2008). Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases. Cancer Chemotherapy and Pharmacology. 63(5). 889–901. 14 indexed citations
15.
López‐Lázaro, Miguel, Elaine Willmore, Sarah L. Elliott, & Caroline A. Austin. (2008). Selenite induces topoisomerase I and II‐DNA complexes in K562 leukemia cells. International Journal of Cancer. 123(9). 2217–2221. 13 indexed citations
16.
Willmore, Elaine, et al.. (1998). Etoposide targets topoisomerase IIα and IIβ in leukemic cells: Isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Molecular Pharmacology. 28 indexed citations
17.
Willmore, Elaine, et al.. (1996). Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180). Molecular Pharmacology. 14 indexed citations
18.
Austin, Caroline A., et al.. (1995). Expression, Domain Structure, and Enzymatic Properties of an Active Recombinant Human DNA Topoisomerase IIβ. Journal of Biological Chemistry. 270(26). 15739–15746. 98 indexed citations
19.
Jones, Suzanne F., Elaine Willmore, & Barbara W. Durkacz. (1994). The effects of 5-fluoropyrimidines on nascent DNA synthesis in Chinese hamster ovary cells monitored by pH-step alkaline and neutral elution. Carcinogenesis. 15(11). 2435–2438. 5 indexed citations
20.
Willmore, Elaine & Barbara W. Durkacz. (1993). Cytotoxic mechanisms of 5-fluoropyrimidines. Biochemical Pharmacology. 46(2). 205–211. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brent D. G. Page Breakdown of academic impact, for papers by Wilberto Nieves‐Neira Breakdown of academic impact, for papers by Dale Grabowski Breakdown of academic impact, for papers by Victoria J. Spanswick Breakdown of academic impact, for papers by Yi‐He Ling Breakdown of academic impact, for papers by Karen S. Flatten Breakdown of academic impact, for papers by Jean‐Marc Barret Breakdown of academic impact, for papers by Yoji Ikegami Breakdown of academic impact, for papers by Fumihiko Kanzawa Breakdown of academic impact, for papers by Erkan Baloglu
Rankless by CCL
2026